(Q40338034)

19 September 2017

title

SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells (English)

1 reference

19 September 2017

Xiao-Feng Zhu

1

1 reference

19 September 2017

Jing-Song Wang

2

1 reference

19 September 2017

Li-Ling Cai

3

1 reference

19 September 2017

Yi-Xin Zeng

4

1 reference

19 September 2017

Dajun Yang

5

1 reference

19 September 2017

publication date

1 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

97

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

84-89

1 reference

Role of HER2/neu in tumor progression and therapy

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Newer therapies in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Prognostic value of the quantitative measurement of the oncoprotein p185(Her-2/neu) in a group of patients with breast cancer and positive node involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00143.X

10.1111/J.1349-7006.2006.00143.X

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference